Sp1 inhibition-mediated upregulation of VEGF165b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549

Tumor Biology

Volumn 32, Issue 4, 2011, Pages 677-687

  Li, Zhen Yu ^a   Zhu, Fang ^a   Hu, Jian Li ^a   Peng, Gang ^a   Chen, Jing ^a   Zhang, Sheng ^a   Chen, Xu ^a   Zhang, Rui Guang ^a   Chen, Ling Juan ^a   Liu, Pian ^a   Luo, Ming ^a   Sun, Zhi Hua ^a   Ren, Jing Hua ^a   Huang, Li Li ^a   Wu, Gang ^a  

^a UNION HOSPITAL   (China)

Author keywords

NSCLC; Rh endostatin; Sp1; VEGF

Indexed keywords

BETULIC ACID; ENDOSTAR; GROWTH FACTOR; RECOMBINANT ENDOSTATIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN 165B; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

EID: 80052321435     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0168-3     Document Type: Article

References (29)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6. (Pubitemid 20020880)
2. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-4. (Pubitemid 23132159)
3. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-85. (Pubitemid 28015876)
4. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell. 1994;79:315-28. (Pubitemid 24324921)
5. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. Vegf165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123-31. (Pubitemid 34791084)
6. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, et al. Expression of pro- and anti-angiogenic isoforms of vegf is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121:3487-95.
7. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48:2422-7. (Pubitemid 41618935)
8. Woolard J,WangWY, BevanHS, QiuY,Morbidelli L, Pritchard-Jones RO, et al. Vegf165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822-35. (Pubitemid 39446915)
9. Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, et al. Vegf 165 b, an antiangiogenic vegf-a isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic vegf-a isoforms has implications for therapy. Br J Cancer. 2008;98:1366-79. (Pubitemid 351543576)
10. Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H, et al. Expression of vegf(xxx)b, the inhibitory isoforms of vegf, in malignant melanoma. Br J Cancer. 2007;97:223-30. (Pubitemid 47057469)
11. Diaz R, Pena C, Silva J, Lorenzo Y, Garcia V, Garcia JM, et al. P73 isoforms affect vegf, vegf165b and pedf expression in human colorectal tumors: Vegf165b downregulation as a marker of poor prognosis. Int J Cancer. 2008;123:1060-7.
12. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, Magnussen A, Schuler Y, Kelly SP, et al. Recombinant human vegf165b protein is an effective anti-cancer agent in mice. Eur J Cancer. 2008;44:1883-94.
13. Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard J, et al. The endogenous anti-angiogenic vegf isoform, vegf165b inhibits human tumour growth in mice. Br J Cancer. 2008;98:1250-7. (Pubitemid 351481687)
14. Kim HS, Lim SJ, Park YK. Anti-angiogenic factor endostatin in osteosarcoma. APMIS. 2009;117:716-23.
15. Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev. 2000;19:181-90. (Pubitemid 32004708)
16. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999;274:11721-6.
17. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, et al. Endostatin inhibits vegf-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999;18:4414-23. (Pubitemid 29391251)
18. Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with kdr/flk-1. J Biol Chem. 2002;277:27872-9. (Pubitemid 34966733)
19. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-7. (Pubitemid 28027321)
20. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking vegf-induced tyrosine phosphorylation of kdr/flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361:79-84. (Pubitemid 47102270)
21. Song HF, Liu XW, Zhang HN, Zhu BZ, Yuan SJ, Liu SY, et al. Pharmacokinetics of his-tag recombinant human endostatin in rhesus monkeys. Acta Pharmacol Sin. 2005;26:124-8.
22. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002;16:1802-4.
23. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of sp-1. J Biol Chem. 1996;271:28220-8. (Pubitemid 26374633)
24. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the pkc beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer. 2008;99:750-9.
25. Chen WC, McBride WH, Iwamoto KS, Barber CL, Wang CC, Oh YT, et al. Induction of radioprotective peroxiredoxin-i by ionizing irradiation. J Neurosci Res. 2002;70:794-8. (Pubitemid 35416896)
26. Jeong HW, Nam JO, Kim IS. The cooh-terminal end of r-ras alters the motility and morphology of breast epithelial cells through rho/ rho-kinase. Cancer Res. 2005;65:507-15.
27. Xu L, Deng X. Protein kinase ciota promotes nicotine-induced migration and invasion of cancer cells via phosphorylation of micro- and m-calpains. J Biol Chem. 2006;281:4457-66. (Pubitemid 43847877)
28. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 2007;67:2816-23. (Pubitemid 46548971)
29. Eremeeva ME, Silverman DJ. Rickettsia rickettsii infection of the ea.Hy 926 endothelial cell line: morphological response to infection and evidence for oxidative injury. Microbiology. 1998;144:2037-48. (Pubitemid 28403016)